Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis

Summary

The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 50 weeks.

Timeline

Start

2015-08-15

Primary completion

2017-09-03

Completion

2017-09-03

Drugs

Indications